Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Spero Therapeutics, Inc. (SPRO : NSDQ)
 
 • Company Description   
Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

Number of Employees: 32

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.91 Daily Weekly Monthly
20 Day Moving Average: 1,418,628 shares
Shares Outstanding: 55.91 (millions)
Market Capitalization: $162.70 (millions)
Beta: 1.33
52 Week High: $3.09
52 Week Low: $0.51
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 16.40% 11.23%
12 Week 385.00% 314.25%
Year To Date 182.52% 164.63%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
675 Massachusetts Avenue 14th Floor
-
Cambridge,MA 02139
USA
ph: 857-242-1600
fax: -
ir@sperotherapeutics.com https://sperotherapeutics.com
 
 • General Corporate Information   
Officers
Esther Rajavelu - Chief Executive Officer; Chief Financial Officer;
Milind Deshpande - Director
Scott Jackson - Director
Cynthia Smith - Director
Kathleen Tregoning - Director

Peer Information
Spero Therapeutics, Inc. (CORR.)
Spero Therapeutics, Inc. (RSPI)
Spero Therapeutics, Inc. (CGXP)
Spero Therapeutics, Inc. (BGEN)
Spero Therapeutics, Inc. (GTBP)
Spero Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 84833T103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
Share - Related Items
Shares Outstanding: 55.91
Most Recent Split Date: (:1)
Beta: 1.33
Market Capitalization: $162.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.43 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.81
Price/Cash Flow: -
Price / Sales: 3.65
EPS Growth
vs. Year Ago Period: -4.17%
vs. Previous Quarter: 34.21%
Sales Growth
vs. Year Ago Period: -36.61%
vs. Previous Quarter: -60.95%
ROE
06/30/25 - -
03/31/25 - -123.50
12/31/24 - -95.11
ROA
06/30/25 - -
03/31/25 - -58.96
12/31/24 - -48.69
Current Ratio
06/30/25 - -
03/31/25 - 2.56
12/31/24 - 2.19
Quick Ratio
06/30/25 - -
03/31/25 - 2.56
12/31/24 - 2.19
Operating Margin
06/30/25 - -
03/31/25 - -156.48
12/31/24 - -142.91
Net Margin
06/30/25 - -
03/31/25 - -156.48
12/31/24 - -142.91
Pre-Tax Margin
06/30/25 - -
03/31/25 - -156.48
12/31/24 - -142.91
Book Value
06/30/25 - -
03/31/25 - 0.60
12/31/24 - 0.85
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©